Onychomycosis
Conditions
Interventions
None listed
Sponsors
Sato Pharmaceutical Co.,Ltd
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patient diagnosed as onychomycosis on either toenail of toe I to toe III by direct microscopy and/or fungal culture at the time of initiation of fosravuconazole treatment 2) Patients who started fosravuconazole treatment according to the medical package insert between June 1st, 2019 and April 30th, 2020
Exclusion criteria
Exclusion criteria: 1) Patients with significant nail thickening, deformity, or discoloration due to diseases such as palmoplantar pustulosis of the nails, psoriasis vulgaris, lichen planus of the nails, pachyonychia, tumor under the nails, onychogryphosis, etc. 2) Patients who have refused to provide medical information for this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical cure rate at 48 weeks of fosravuconazole administration | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Change in clinical cure rate at 12, 24, 36 and 48 weeks of fosravuconazole administration 2) Change in mycological cure rate at 12, 24, 36 and 48 weeks of fosravuconazole administration 3) Days to clinical cure 4) Change in nail involvement ratio at 12, 24, 36 and 48 weeks of fosravuconazole administration 5) Percent decrease in nail involvement ratio at 12, 24, 36 and 48 weeks of fosravuconazole administration | — |
Countries
Japan
Contacts
Public ContactYuki Murabayashi
Mebix, Inc. Clinical Research Operation
Outcome results
None listed